
    
      Part 1: Approximately 40 subjects randomized into 5 cohorts to receive PN-235 or placebo as
      single doses.

      Part 2: Approximately 50 subjects enrolled into 5 cohorts to receive PN-235 or placebo once
      daily for 10 days.

      Part 3: Twelve subjects will receive single doses of PN-235 in a 4-way, randomized, crossover
      fashion.

      In total, approximately 102 subjects will participate.
    
  